420 related articles for article (PubMed ID: 28496549)
1. Phosphodiesterase-5 Inhibitors Improve Clinical Outcomes, Exercise Capacity and Pulmonary Hemodynamics in Patients With Heart Failure With Reduced Left Ventricular Ejection Fraction: A Meta-Analysis.
De Vecchis R; Cesaro A; Ariano C; Giasi A; Cioppa C
J Clin Med Res; 2017 Jun; 9(6):488-498. PubMed ID: 28496549
[TBL] [Abstract][Full Text] [Related]
2. Differential effects of the phosphodiesterase inhibition in chronic heart failure depending on the echocardiographic phenotype (HFREF or HFpEF): a meta-analysis.
De Vecchis R; Cesaro A; Ariano C
Minerva Cardioangiol; 2018 Oct; 66(5):659-670. PubMed ID: 28398017
[TBL] [Abstract][Full Text] [Related]
3. Therapeutic benefits of phosphodiesterase-5 inhibition in chronic heart failure: A meta-analysis.
Vecchis R; Cesaro A; Ariano C
Interv Med Appl Sci; 2017 Sep; 9(3):123-135. PubMed ID: 29201436
[TBL] [Abstract][Full Text] [Related]
4. Phosphodiesterase inhibitor for heart failure with preserved ejection fraction: A systematic review and meta-analysis.
Chen Z; Zhao K; Xiao C; He Z; Liu S; Wu X; Shi S; Guo Y
Saudi Pharm J; 2022 Aug; 30(8):1079-1087. PubMed ID: 36164567
[TBL] [Abstract][Full Text] [Related]
5. Pulmonary hemodynamics and effects of phosphodiesterase type 5 inhibition in heart failure: a meta-analysis of randomized trials.
Hwang IC; Kim YJ; Park JB; Yoon YE; Lee SP; Kim HK; Cho GY; Sohn DW
BMC Cardiovasc Disord; 2017 Jun; 17(1):150. PubMed ID: 28606099
[TBL] [Abstract][Full Text] [Related]
6. Aldosterone receptor antagonists decrease mortality and cardiovascular hospitalizations in chronic heart failure with reduced left ventricular ejection fraction, but not in chronic heart failure with preserved left ventricular ejection fraction: a meta-analysis of randomized controlled trials.
DE Vecchis R; Ariano C
Minerva Cardioangiol; 2017 Aug; 65(4):427-442. PubMed ID: 27958695
[TBL] [Abstract][Full Text] [Related]
7. Differential efficacy profile of aldosterone receptor antagonists, depending on the type of chronic heart failure, whether with reduced or preserved left ventricular ejection fraction-results of a meta-analysis of randomized controlled trials.
De Vecchis R; Ariano C
Cardiovasc Diagn Ther; 2017 Jun; 7(3):272-287. PubMed ID: 28567353
[TBL] [Abstract][Full Text] [Related]
8. Phosphodiesterase 5 inhibitor sildenafil in patients with heart failure with preserved ejection fraction and combined pre- and postcapillary pulmonary hypertension: a randomized open-label pilot study.
Belyavskiy E; Ovchinnikov A; Potekhina A; Ageev F; Edelmann F
BMC Cardiovasc Disord; 2020 Sep; 20(1):408. PubMed ID: 32912157
[TBL] [Abstract][Full Text] [Related]
9. PDE 5 inhibition with udenafil improves left ventricular systolic/diastolic functions and exercise capacity in patients with chronic heart failure with reduced ejection fraction; A 12-week, randomized, double-blind, placebo-controlled trial.
Kim KH; Kim HK; Hwang IC; Cho HJ; Je N; Kwon OM; Choi SJ; Lee SP; Kim YJ; Sohn DW
Am Heart J; 2015 Jun; 169(6):813-822.e3. PubMed ID: 26027619
[TBL] [Abstract][Full Text] [Related]
10. PDE5 inhibitor sildenafil in the treatment of heart failure: a meta-analysis of randomized controlled trials.
Zhuang XD; Long M; Li F; Hu X; Liao XX; Du ZM
Int J Cardiol; 2014 Apr; 172(3):581-7. PubMed ID: 24534379
[TBL] [Abstract][Full Text] [Related]
11. Sacubitril/Valsartan in the Treatment of Heart Failure With Reduced Ejection Fraction Focusing on the Impact on the Quality of Life: A Systematic Review and Meta-Analysis of Randomized Clinical Trials.
Bhattacharjee P; Khan Z
Cureus; 2023 Nov; 15(11):e48674. PubMed ID: 38090453
[TBL] [Abstract][Full Text] [Related]
12. Ivabradine Improves Cardiac Function and Increases Exercise Capacity in Patients with Chronic Heart Failure.
Pei H; Miao W; Xie WZ; Wang W; Zhao D; Su GH; Zhao Z
Int Heart J; 2019 Jul; 60(4):899-909. PubMed ID: 31308326
[TBL] [Abstract][Full Text] [Related]
13. The Impact Exerted on Clinical Outcomes of Patients With Chronic Heart Failure by Aldosterone Receptor Antagonists: A Meta-Analysis of Randomized Controlled Trials.
De Vecchis R; Cantatrione C; Mazzei D; Barone A; Maurea N
J Clin Med Res; 2017 Feb; 9(2):130-142. PubMed ID: 28090229
[TBL] [Abstract][Full Text] [Related]
14. Right ventricular dysfunction in left-sided heart failure with preserved versus reduced ejection fraction.
Bosch L; Lam CSP; Gong L; Chan SP; Sim D; Yeo D; Jaufeerally F; Leong KTG; Ong HY; Ng TP; Richards AM; Arslan F; Ling LH
Eur J Heart Fail; 2017 Dec; 19(12):1664-1671. PubMed ID: 28597497
[TBL] [Abstract][Full Text] [Related]
15. Additional use of a phosphodiesterase 5 inhibitor in patients with pulmonary hypertension secondary to chronic systolic heart failure: a meta-analysis.
Wu X; Yang T; Zhou Q; Li S; Huang L
Eur J Heart Fail; 2014 Apr; 16(4):444-53. PubMed ID: 24464734
[TBL] [Abstract][Full Text] [Related]
16. Impact of ivabradine on the cardiac function of chronic heart failure reduced ejection fraction: Meta-analysis of randomized controlled trials.
Bryan Richard S; Huang B; Liu G; Yang Y; Luo S
Clin Cardiol; 2021 Apr; 44(4):463-471. PubMed ID: 33638556
[TBL] [Abstract][Full Text] [Related]
17. Effects of sildenafil on invasive haemodynamics and exercise capacity in heart failure patients with preserved ejection fraction and pulmonary hypertension: a randomized controlled trial.
Hoendermis ES; Liu LC; Hummel YM; van der Meer P; de Boer RA; Berger RM; van Veldhuisen DJ; Voors AA
Eur Heart J; 2015 Oct; 36(38):2565-73. PubMed ID: 26188003
[TBL] [Abstract][Full Text] [Related]
18. Comparative effectiveness of sildenafil for pulmonary hypertension due to left heart disease with HFrEF.
Jiang R; Wang L; Zhu CT; Yuan P; Pudasaini B; Zhao QH; Gong SG; He J; Liu JM; Hu QH
Hypertens Res; 2015 Dec; 38(12):829-39. PubMed ID: 26202179
[TBL] [Abstract][Full Text] [Related]
19. Heart Failure and Midrange Ejection Fraction: Implications of Recovered Ejection Fraction for Exercise Tolerance and Outcomes.
Nadruz W; West E; Santos M; Skali H; Groarke JD; Forman DE; Shah AM
Circ Heart Fail; 2016 Apr; 9(4):e002826. PubMed ID: 27009553
[TBL] [Abstract][Full Text] [Related]
20. Effects of sildenafil on symptoms and exercise capacity for heart failure with reduced ejection fraction and pulmonary hypertension (the SilHF study): a randomized placebo-controlled multicentre trial.
Cooper TJ; Cleland JGF; Guazzi M; Pellicori P; Ben Gal T; Amir O; Al-Mohammad A; Clark AL; McConnachie A; Steine K; Dickstein K
Eur J Heart Fail; 2022 Jul; 24(7):1239-1248. PubMed ID: 35596935
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
